Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19823045 | 0.89 | TNIK (0.54) | CCNT1CCNA2CDK2CDK9TNIK | |
| SCHEMBL19823067 | 0.86 | TNIK (0.68) | LRRK2MAP4K1CDK2TNIKCDK1 | |
| SCHEMBL19823109 | 0.85 | TNIK (0.53) | CDK2TNIKDRD4HTR2ADRD2 | |
| SCHEMBL19823048 | 0.84 | TNIK (0.52) | TNIKDRD4HTR2ADRD2DRD3 | |
| SCHEMBL19823047 | 0.84 | TNIK (0.49) | CDK2CDK9TNIKDYRK1ACDK1 | |
| SCHEMBL4792087 | 0.82 | NEK1 (0.62) | LRRK2MAP4K1CDK2CDK9HRH3 | |
| SCHEMBL857712 | 0.80 | DRD4 (0.74) | DRD4HTR2ADRD2DRD3HTR7 | |
| SCHEMBL21044844 | 0.79 | CAMKK2 (0.54) | CDK2CDK9TNIKDYRK1ACDK1 | |
| SCHEMBL19119615 | 0.78 | MAP4K1 (0.56) | LRRK2MAP4K1CDK2HRH3TNIK | |
| SCHEMBL21506287 | 0.78 | CCNC (0.49) | LRRK2MAP4K1CCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | claimed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | claimed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | claimed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| CN-109843883-B | Compounds as selective JAK inhibitors, salts of the compounds and therapeutic uses thereof | 苏州隆博泰药业有限公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018019223-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | 张文燕 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | JAK1, JAK2, JAK3 | LRRK2 407/4885MAP4K1 141/4885CCNT1 872/4885 |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | JAK1, JAK2, JAK3 | LRRK2 407/4885MAP4K1 141/4885CCNT1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.